Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany:
Gespeichert in:
| Beteiligte Personen: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Erlangen ; Nürnberg
Friedrich-Alexander-Universität Erlangen-Nürnberg
2020
|
| Schlagwörter: | |
| Links: | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-155904 https://d-nb.info/1225123690/34 https://open.fau.de/handle/openfau/15590 |
| Umfang: | 1 Online-Ressource |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047112943 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 210129s2020 gw o|||| 00||| eng d | ||
| 015 | |a 21,O02 |2 dnb | ||
| 016 | 7 | |a 1225123690 |2 DE-101 | |
| 024 | 7 | |a urn:nbn:de:bvb:29-opus4-155904 |2 urn | |
| 035 | |a (OCoLC)1235891513 | ||
| 035 | |a (DE-599)DNB1225123690 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-29 | ||
| 084 | |8 1\p |a 616.994 |2 23ksdnb | ||
| 084 | |8 2\p |a 610 |2 23sdnb | ||
| 100 | 1 | |a Schneeweiss, Andreas |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |c Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere] |
| 264 | 1 | |a Erlangen ; Nürnberg |b Friedrich-Alexander-Universität Erlangen-Nürnberg |c 2020 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 583 | 1 | |a Archivierung/Langzeitarchivierung gewährleistet |5 DE-101 |2 pdager | |
| 653 | |a Advanced breast cancer | ||
| 653 | |a Metastatic | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Endocrine therapy | ||
| 653 | |a CDK4/6 | ||
| 653 | |a Ribociclib | ||
| 653 | |a Palbociclib | ||
| 653 | |a Abemaciclib | ||
| 700 | 1 | |a Ettl, Johannes |e Verfasser |4 aut | |
| 700 | 1 | |a Lüftner, Diana |e Verfasser |4 aut | |
| 787 | 0 | 8 | |i Sonderdruck aus |t The Breast |g Vol. 54 (2020), Seite 88 - 95 |o 10.1016/j.breast.2020.08.011 |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-155904 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://d-nb.info/1225123690/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |q application/pdf |u https://open.fau.de/handle/openfau/15590 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 883 | 0 | |8 1\p |a aepkn |c 0,99974 |d 20210116 |q DE-101 |u https://d-nb.info/provenance/plan#aepkn | |
| 883 | 0 | |8 2\p |a aepsg |c 1,00000 |d 20210116 |q DE-101 |u https://d-nb.info/provenance/plan#aepsg | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-032519380 | |
Datensatz im Suchindex
| _version_ | 1818987648758317056 |
|---|---|
| any_adam_object | |
| author | Schneeweiss, Andreas Ettl, Johannes Lüftner, Diana |
| author_facet | Schneeweiss, Andreas Ettl, Johannes Lüftner, Diana |
| author_role | aut aut aut |
| author_sort | Schneeweiss, Andreas |
| author_variant | a s as j e je d l dl |
| building | Verbundindex |
| bvnumber | BV047112943 |
| collection | ebook |
| ctrlnum | (OCoLC)1235891513 (DE-599)DNB1225123690 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02297nam a2200529zc 4500</leader><controlfield tag="001">BV047112943</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">210129s2020 gw o|||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">21,O02</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1225123690</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-155904</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1235891513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1225123690</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">616.994</subfield><subfield code="2">23ksdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">2\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schneeweiss, Andreas</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany</subfield><subfield code="c">Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen ; Nürnberg</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">Archivierung/Langzeitarchivierung gewährleistet</subfield><subfield code="5">DE-101</subfield><subfield code="2">pdager</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Advanced breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Metastatic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Endocrine therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CDK4/6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ribociclib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Palbociclib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Abemaciclib</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ettl, Johannes</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lüftner, Diana</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="787" ind1="0" ind2="8"><subfield code="i">Sonderdruck aus</subfield><subfield code="t">The Breast</subfield><subfield code="g">Vol. 54 (2020), Seite 88 - 95</subfield><subfield code="o">10.1016/j.breast.2020.08.011</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-155904</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://d-nb.info/1225123690/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="q">application/pdf</subfield><subfield code="u">https://open.fau.de/handle/openfau/15590</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">aepkn</subfield><subfield code="c">0,99974</subfield><subfield code="d">20210116</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#aepkn</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">aepsg</subfield><subfield code="c">1,00000</subfield><subfield code="d">20210116</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#aepsg</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032519380</subfield></datafield></record></collection> |
| id | DE-604.BV047112943 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T19:10:02Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032519380 |
| oclc_num | 1235891513 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| record_format | marc |
| spelling | Schneeweiss, Andreas Verfasser aut Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere] Erlangen ; Nürnberg Friedrich-Alexander-Universität Erlangen-Nürnberg 2020 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Archivierung/Langzeitarchivierung gewährleistet DE-101 pdager Advanced breast cancer Metastatic Chemotherapy Endocrine therapy CDK4/6 Ribociclib Palbociclib Abemaciclib Ettl, Johannes Verfasser aut Lüftner, Diana Verfasser aut Sonderdruck aus The Breast Vol. 54 (2020), Seite 88 - 95 10.1016/j.breast.2020.08.011 https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-155904 Resolving-System kostenfrei Volltext https://d-nb.info/1225123690/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext application/pdf https://open.fau.de/handle/openfau/15590 Verlag kostenfrei Volltext 1\p aepkn 0,99974 20210116 DE-101 https://d-nb.info/provenance/plan#aepkn 2\p aepsg 1,00000 20210116 DE-101 https://d-nb.info/provenance/plan#aepsg |
| spellingShingle | Schneeweiss, Andreas Ettl, Johannes Lüftner, Diana Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |
| title | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |
| title_auth | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |
| title_exact_search | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |
| title_full | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere] |
| title_fullStr | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere] |
| title_full_unstemmed | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany Andreas Schneeweiss, Johannes Ettl, Diana Lüftner [und 31 weitere] |
| title_short | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany |
| title_sort | initial experience with cdk4 6 inhibitor based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive her2 negative breast cancer data from the praegnant research network for the first 2 years of drug availability in germany |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-155904 https://d-nb.info/1225123690/34 https://open.fau.de/handle/openfau/15590 |
| work_keys_str_mv | AT schneeweissandreas initialexperiencewithcdk46inhibitorbasedtherapiescomparedtoantihormonemonotherapiesinroutineclinicaluseinpatientswithhormonereceptorpositiveher2negativebreastcancerdatafromthepraegnantresearchnetworkforthefirst2yearsofdrugavailabilityingermany AT ettljohannes initialexperiencewithcdk46inhibitorbasedtherapiescomparedtoantihormonemonotherapiesinroutineclinicaluseinpatientswithhormonereceptorpositiveher2negativebreastcancerdatafromthepraegnantresearchnetworkforthefirst2yearsofdrugavailabilityingermany AT luftnerdiana initialexperiencewithcdk46inhibitorbasedtherapiescomparedtoantihormonemonotherapiesinroutineclinicaluseinpatientswithhormonereceptorpositiveher2negativebreastcancerdatafromthepraegnantresearchnetworkforthefirst2yearsofdrugavailabilityingermany |